Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Levels of 25(OH)D remained unchanged at 39.7 (SD5) ng/dL by the end of the study with nine pwCF still exhibiting inadequate vitamin D levels.

Source: Vitamin D. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis

Study design awaiting verification · Pediatric Pulmonology · 2025

Original publication title

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis

Susanne Ursula Trost; Tasma Harindhanavudhi; Qi Wang; Anvitha Ankireddypalli; Azmi Simrah; Sreekant Avula; Amir Moheet

© 2025 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Bone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow‐up at 4 years post‐ETI treatment, suggesting potential bone‐protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF‐related bone disease and body composition remain unclear.

Source: Background

Abstract: What methods does the paper describe?

This retrospective real‐world study examined adults with CF who received ETI treatment. Bone density and body composition were measured via dual‐energy X‐ray absorptiometry (DXA) 1.8 (SD 0.7) years before (preDXA) and 1.5 (SD 0.4) years after ETI initiation (postDXA1). In a subgroup, measurements were also available 4 (SD 0.6) years after initiation (postDXA2).

Source: Methods

Abstract: Results

The study included 74 pwCF, of whom 42% were female, with an average age of 38.9 (SD 9.3) years at ETI initiation. Bone density decreased significantly at the spine (p = 0.02), left hip (p < 0.01), and right hip (p < 0.01) from pre‐ to postDXA1. No significant change in bone density was observed when comparing postDXA1 to postDXA2. Body composition analysis revealed significant increases in weight in both females (p < 0.01) and males (p < 0.01), as well as increases in fat mass in females (p < 0.01) and males (p < 0.01), without significant changes in lean mass (p = 0.4).

Source: Results

Abstract: Conclusions

Bone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow‐up at 4 years post‐ETI treatment, suggesting potential bone‐protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF‐related bone disease and body composition remain unclear.

Methods

This retrospective real‐world study examined adults with CF who received ETI treatment. Bone density and body composition were measured via dual‐energy X‐ray absorptiometry (DXA) 1.8 (SD 0.7) years before (preDXA) and 1.5 (SD 0.4) years after ETI initiation (postDXA1). In a subgroup, measurements were also available 4 (SD 0.6) years after initiation (postDXA2).

Results

The study included 74 pwCF, of whom 42% were female, with an average age of 38.9 (SD 9.3) years at ETI initiation. Bone density decreased significantly at the spine (p = 0.02), left hip (p < 0.01), and right hip (p < 0.01) from pre‐ to postDXA1. No significant change in bone density was observed when comparing postDXA1 to postDXA2. Body composition analysis revealed significant increases in weight in both females (p < 0.01) and males (p < 0.01), as well as increases in fat mass in females (p < 0.01) and males (p < 0.01), without significant changes in lean mass (p = 0.4).

Conclusions

Bone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow‐up at 4 years post‐ETI treatment, suggesting potential bone‐protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.

Publication and source details

Original title: Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis

Susanne Ursula Trost; Tasma Harindhanavudhi; Qi Wang; Anvitha Ankireddypalli; Azmi Simrah; Sreekant Avula; Amir Moheet

Pediatric Pulmonology · 2025

* Correspondence: Susanne Ursula Trost (trost096@umn.edu)
© 2025 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. The authors received no specific funding for this work.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:08:41.737105+00:00

DOI: 10.1002/ppul.71280 · PMC12418912